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Murine IgG3 anti-GD2 antibody m3F8 has shown anti-neuroblastoma activity in Phase I/II studies, where antibody-
dependent cell-mediated cytotoxicity (ADCC) played a key role. Humanization of m3F8 should circumvent human anti-
mouse antibody (HAMA) response and enhance its ADCC properties to reduce dosing and pain side effect. Chimeric 3F8
(ch3F8) and humanized 3F8 (hu3F8-IgG1 and hu3F8-IgG4) were produced and purified by protein A affinity
chromatography. In vitro comparison was made with m3F8 and other anti-GD2 antibodies in binding, cytotoxicity, and
cross-reactivity assays. In GD2 binding studies by SPR, ch3F8 and hu3F8 maintained KD comparable to m3F8. Unlike other
anti-GD2 antibodies, m3F8, ch3F8 and hu3F8 had substantially slower koff.. Similar to m3F8, both ch3F8 and hu3F8
inhibited tumor cell growth in vitro, while cross-reactivity with other gangliosides was comparable to that of m3F8. Both
peripheral blood mononuclear cell (PBMC)-ADCC and polymorphonuclear leukocytes (PMN)-ADCC of ch3F8 and hu3F8-
IgG1 were more potent than m3F8. This superiority was consistently observed in ADCC assays, irrespective of donors or
NK-92MI-transfected human CD16 or CD32, whereas complement mediated cytotoxicity (CMC) was reduced. As
expected, hu3F8-IgG4 had near absent PBMC-ADCC and CMC. Hu3F8 and m3F8 had similar tumor-to-non tumor ratios in
biodistribution studies. Anti-tumor effect against neuroblastoma xenografts was better with hu3F8-IgG1 than m3F8.
In conclusion, humanizing m3F8 produced next generation anti-GD2 antibodies with substantially more potent ADCC in
vitro and anti-tumor activity in vivo. By leveraging ADCC over CMC, they may be clinically more effective, while
minimizing pain and HAMA side effects. A Phase I trial using hu3F8-IgG1 is ongoing.
Introduction
Monoclonal antibody (MoAb) therapy is an accepted treatment
modality for cancers, with five MoAb having received FDA
approval for solid tumors in adults, including colorectal and breast
cancer, non small cell lung cancer, squamous cell carcinoma and
melanoma.
1,2 This modality, however, has remained inadequately
exploited for the treatment of pediatric cancers. Unlike chemo-
therapy or radiation, MoAb is not myelosuppressive and geno-
toxic, generally with few long-term toxicities. These are critical
considerations for young children. More importantly, MoAb is
effective against metastatic cancer in blood, bone marrow and
bone, typically found in high risk neuroblastoma (NB). As a class
of agents, the pharmacokinetics and toxicities of human or
humanized IgG1 antibodies have been extensively studied. In
addition, antibodies can carry cytotoxic immune-based payloads,
as well as radioisotopes, toxins or enzymes, thereby increasing the
options for targeted therapy.
NB is the most common extracranial solid tumor of child-
hood. In ~50% of cases, curative strategies must tackle both soft
tissue mass and metastases in the bone marrow (BM). Dose-
intensive chemotherapy improves tumor resectability and post-
surgical irradiation reduces the risk of relapse in the primary site
to , 10%.
3 However, BM disease, as evidenced by histology
or metaiodobenzylguanidine (MIBG) scan, often persists and
forebodes a lethal outcome.
4,5 In addition, osteomedullary relapse
is common, despite achieving near complete remission after
induction therapy. Attempts at treatment intensification have
met with acute and long-term side effects, both of grave concern
for young patients. There is a scarcity of promising new
agents, and to date, few if any target/pathway-specific small
molecules have shown major clinical benefit in patients with
NB, although many promising leads continue to accumulate.
6
With a cure rate of , 30% at toxicity limits among Stage 4
patients diagnosed at $ 18 mo of age, there is substantial room
for improvement.
7
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Ganglioside GD2 is an adhesion molecule abundant on NB.
It is an ideal target for MoAb-based therapy in NB. Anti-GD2
MoAb mediates highly efficient antibody-dependent cell-
mediated cytotoxicity (ADCC) of NB in the presence of human
white cells. It also induces complement mediated cytotoxicity
(CMC) of NB cells, which lack decay accelerating factor CD55
8
and homologous restriction factor CD59.
9 Complement deposi-
tion on NB cells enhances ADCC through activation of the
iC3b receptor on neutrophils,
10,11 available even after dose-
intensive or myeloablative chemotherapy plus stem cell trans-
plant, provided colony stimulating factors are given.
12 Moreover,
the use of intensive chemotherapy, which is standard of care
for NB to achieve clinical remission, will result in prolonged
lymphopenia and immunosuppression,
13 such that patients are
less likely to reject murine or chimeric MoAb.
14
At least two antibody families have been tested clinically,
i.e., 3F8
15 and 14.18.
16 Chimeric (ch) 14.18 and 14.G2a were
both derived from the variable region of murine MoAb 14.18.
17
They demonstrate ADCC and CMC of NB and melanoma
cells in vivo.
18-21 Based on encouraging clinical responses in
Phase I studies, ch14.18 was tested in large Phase II studies as
consolidation therapy for Stage 4 NB (German NB90 and NB97
studies). For the 166 patients . 12 mo at diagnosis, even though
event free survival was similar in patients receiving ch14.18 when
compared with patients on maintenance chemotherapy, overall
survival improved, and the rate of BM relapse was reduced.
22
In 2001, the Children’s Oncology Group (COG) initiated a
randomized Phase III trial to study the efficacy of the com-
bination of ch14.18 with GM-CSF and IL-2 in preventing NB
relapse in patients in complete remission after autologous
stem cell transplant.
23 An interim analysis showed a statistically
significant improvement in PFS and OS at 2 y.
24
m3F8, a murine IgG3 MoAb specific for GD2, also induces
cell death, and mediates efficient ADCC and CMC against NB
in vitro.
15 Among patients with chemo-resistant marrow disease
despite dose-intensive induction plus an aggressive salvage
regimen, 80% achieved BM remission usually after 1 to 2 cycles
of 5 days of m3F8 plus GM-CSF immunotherapy.
25 Given the
activity of m3F8 against chemo-resistant marrow disease, its use
was expanded to patients in their first remission with encourag-
ing results.
26 These favorable clinical outcomes in children could
be improved if 3F8 is given as maintenance therapy over the
first 3–5 y of highest recurrence risk. However, human anti-
mouse antibody (HAMA) is a limiting factor when the immune
system recovers following cessation of chemotherapy. One
strategy to reduce HAMA is to chimerize or humanize 3F8,
which is the subject of this report.
Results
Amino acid sequences of chimeric-3F8 and humanized-3F8-
IgG1/IgG4. The CDRs of the heavy and light chains of m3F8
were grafted onto human IgG1 frameworks based on their
homology with human frameworks IGG HV3-33 and IGKV3-
15, respectively. The amino acid sequences of chimeric and
humanized heavy and light chains are shown in Table1 and
Table2, respectively. Additional constructs were made replacing
the heavy chain sequences of m3F8 and hu3F8-IgG1 with the
human IgG4 framework (Table3), transfected into DG44 cells
using the bluescript vectors. Both chimeric and humanized 3F8
were purified using standard protein A affinity chromatography.
On SDS gel, chimeric and humanized antibodies migrated as
IgG with the appropriate size heavy and light chains; and by
HPLC they all eluted as whole IgG with , 10% aggregate
formation (data not shown). By ELISA they all bound to GD2
with similar avidity.
Binding kinetics by surface plasmon resonance (SPR). With
antigen GD2 coated onto CM5 chips, kinetics of antibody
Table1. Amino acid sequences of chimeric 3F8 heavy and light chains with CDR regions
Ch3F8 heavy chain-gamma1
QVQLKESGPGLVAPSQSLSITCTVSGFSVTNYGVHWVRQPPGKGLEWLGVIWAGGITNYNSAFMSRLSISKDNSKSQVFLKMNSLQIDDTAMYYCASRGGHYGYALDY
WGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCD
KTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKT
ISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
Ch3F8 light chain-kappa
SIVMTQTPKFLLVSAGDRVTITCKASQSVSNDVTWYQQKAGQSPKLLIYSASNRYSGVPDRFTGSGYGTAFTFTISTVQAEDLAVYFCQQDYSSFGGGTKLEIKRTVAAPSVFI
FPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
Table2. Amino acid sequences of humanized 3F8 heavy and light chain with CDR regions
Hu3F8 heavy chain-gamma1
QVQLVESGPGVVQPGRSLRISCAVSGFSVTNYGVHWVRQPPGKGLEWLGVIWAGGITNYNSAFMSRLTISKDNSKNTVYLQMNSLRAEDTAMYYCASRGGHYGYALDY
WGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSC
DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEK
TISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
Hu3F8 light chain-kappa
EIVMTQTPATLSVSAGERVTITCKASQSVSNDVTWYQQKPGQAPRLLIYSASNRYSGVPARFSGSGYGTEFTFTISSVQSEDFAVYFCQQDYSSFGQGTKLEIKRTVAAPS
VFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
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binding (kon,k off and KD) were compared by SPR using Biacore
T-100. All engineered 3F8, including chimeric and humanized
IgG1 and IgG4 had comparable koff as m3F8, and better KD
than other anti-GD2 antibody such as 14.G2a (Fig.1) and
ME36.1 (Table4). The slow koff of antibodies also translated
into a slower wash-off when antibodies were reacted with GD2-
positive tumor cells LAN-1 or M14 and then washed multiple
times in wash buffer. With each wash, the remaining antibodies
on the cell surface were detected using a secondary FITC-labeled
goat anti-mouse antibody and mean fluorescent intensity
determined by flow cytometry (data not shown).
Low cross-reactivity with other gangliosides. In cross-
reactivity studies, hu3F8-H1L1-IgG1 had similar profile as
ch3F8-IgG1 and m3F8 (Table5). There was low level of cross-
reactivity with GD1b expressed as percent OD by ELISA relative
to the OD on solid phase GD2. There was no cross-reactivity
of m3F8, hu3F8 or 14.G2a with human N-CAM,
27 either by
western blots or by SPR (data not shown).
Direct cytotoxicity. When these antibodies were added to
neuroblastoma cells in vitro, they induced direct cell death and
slowed down in vitro cell growth. Upon assayed by WST-8 in
a 3-d culture system, m3F8 and hu3F8 had similar potency
when their EC50s were compared (Table6). In contrast, 14.G2a
was ~10-fold weaker in tumor cell killing.
Antibody potency in ADCC and CMC. Anti-GD2 antibodies
were compared in ADCC assays using PBMC and PMN from
volunteers as effectors and LAN-1 cells as targets. ADCC
potencies of these antibodies were computed as the ratio (EC50
for 3F8)/(EC50 for MoAb) (Table7). Relative to m3F8, ch3F8-
IgG1 and hu3F8-IgG1 were ~300-fold stronger in PBMC-
ADCC, and 18-fold stronger in PMN-ADCC. In addition, the
maximal cytotoxicity achieved with both chimeric and humanized
3F8 of IgG1 subclass were substantially and consistently higher
than that of m3F8 or 14.G2a, irrespective if it was PBMC-
ADCC or PMN-ADCC.
Table3. Amino acid sequences of chimeric and humanized 3F8 heavy chain of the IgG4 subclass with CDR regions
Ch3F8 heavy chain-gamma4
QVQLKESGPGLVAPSQSLSITCTVSGFSVTNYGVHWVRQPPGKGLEWLGVIWAGGITNYNSAFMSRLSISKDNSKSQVFLKMNSLQIDDTAMYYCASRGGHYGYALDY
WGQGTSVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKY
GPPCPSCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKT
ISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK
Hu3F8 heavy chain-gamma4
QVQLVESGPGVVQPGRSLRISCAVSGFSVTNYGVHWVRQPPGKGLEWLGVIWAGGITNYNSAFMSRLTISKDNSKNTVYLQMNSLRAEDTAMYYCASRGGHYGYALDY
WGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYG
PPCPSCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTIS
KAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK
Figure1. Comparative binding kinetics of anti-GD2 antibodies on solid phase GD2 when measured by surface plasmon resonance (Biacore T-100).
Table4. Binding kinetics of chimeric and humanized 3F8 by surface
plasmon resonance
Antibody kon koff KD (nM)
ch3F8-IgG1 1.15E + 05 1.45E − 03 13 ± 3
hu3F8-IgG1 9.19E + 04 1.03E − 03 11 ± 1
ch3F8-IgG4 9.40E + 04 1.28E − 03 14 ± 2
hu3F8-IgG4 1.18E + 05 1.76E − 03 15 ± 1
m3F8 1.74E + 05 8.74E − 04 5 ± 1
14.G2a 1.50E + 05 1.12E − 02 77 ± 8
ME36.1 1.21E + 05 2.79E − 03 19 ± 7
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In order to examine the capability of MoAb in ADCC for
individual FcR in the absence of inhibitory FcR, we tested ADCC
using NK-92MI cells which do not carry human FcR on their
cell surface. Upon transfection with human CD16 and CD32,
they could mediate efficient ADCC. When these effector cells
were used against LAN-1 targets, ch3F8-IgG1 and hu3F8-IgG1
was more efficient (. 10-fold) than m3F8 in CD16-ADCC,
as well as CD32-ADCC. Hu3F8-IgG4 subclass antibodies had
minimal PBMC-ADCC, PMN-ADCC, CD16-ADCC and
CD32 activity when compared with m3F8. In human CMC,
ch3F8, hu3F8 and 14G.2a were not as efficient as m3F8.
A representative panel of human NB cell lines was tested in
cytotoxicity assays (CD16-ADCC, CD32-ADCC and CMC;
Table 8). Even though most NB cell lines were sensitive, those
with low GD2 antigen density (e.g., SKNJC2) were resistant.
Overall, hu3F8 was generally much more efficient than m3F8 in
cytotoxicity.
Targeting human neuroblastoma xenografts. Hu3F8-IgG1
and hu3F8-IgG4 were radiolabeled with
131I. They all had com-
parable immunoreactivity of ~40–45% (data not shown). Their
bio-distributions at 48 h were compared with that of
131I-m3F8
in mice bearing sc LAN-1 xenografts. Tumor uptake when
measured by %ID/gm was comparable between hu3F8-IgG1
(29.6%) and m3F8 (28.6%), nearly double that of hu3F8-IgG4
(Table 9). Tumor to non-tumor ratios was comparable among
these four antibodies.
Treatment of neuroblastoma xenografts using 3F8 antibodies.
LAN-1 is one of the most widely studied human NB cell lines.
Even though the mouse effectors and mouse complement were
generally suboptimal for testing monoclonal antibodies, it is the
only established model for in vivo assays.
28 Mice xenografted with
established human NB LAN-1 (0.5–1 cm diameter) were treated
with iv m3F8 or hu3F8-IgG1 twice weekly for 4 weeks. Tumor
size, weight, and survival were monitored. Hu3F8-IgG1 (100 mg
dose) inhibited tumor growth significantly (p , 0.05), when
compared with m3F8 (200 mg dose) or control mIgG3 (100 mg
dose). At 20 mg dose, hu3F8-IgG1 was not effective (Fig.2).
Hu3F8-IgG1 (200 mg dose) was not more effective than hu3F8-
IgG1 (100 mg dose) (data not shown). Survival of mice receiving
100–200 mg were significantly longer (p = 0.003) than mice
receiving PBS control or m3F8 (data not shown).
Discussion
Anti-GD2 antibody is a proven therapy for GD2-postive NB.
29
Murine antibody 14.18 and its derivatives (14.G2a and ch14.18)
have provided benchmarks for improving anti-GD2 therapy. We
chose murine IgG3 antibody m3F8 for clinical development
because of its 10-fold slower koff, when compared with 14.G2a
in GD2 binding kinetics by SPR. Among patients with chemo-
resistant metastatic NB in the bone marrow, m3F8 plus GM-CSF
induced 80% complete remissions,
30 and among patients with
high risk metastatic NB in first remission, m3F8 plus GM-CSF
was associated with . 75% overall long-term survival.
26 However,
HAMA can diminish the effect of the murine antibody by
neutralizing its ability to bind to its antigen, by blocking the
direct effect of the antibody, and by accelerating the clearance of
the antibody from circulation. Genetic engineering to change
murine to human IgG frameworks should reduce the HAMA
response. Ch14.18
31,32 and hu14.18
33 (both derived from the VH
and VL of 14.G2a) have reduced immunogenicity in some but
not all patients. We therefore tested the chimeric and humanized
forms of 3F8 as potential next generation anti-GD2 antibodies
One criterion for successful chimerization and humanization
is the preservation of affinity during genetic engineering. It was
reassuring that a slow koff in ch3F8 and hu3F8 was maintained.
Table5. Low cross-reactivity with other gangliosides by ELISA (Mean ± SD)
Antibody GM2/GD2 GD1a/GD2 GD1b/GD2 GT1b/GD2 GD3/GD2 GQ1b/GD2
ch3F8-IgG1 0% 0.2% ± 0.9% 8.8% ± 0.8% 0% 0.2% ± 0.9% 0%
hu3F8-IgG1 0% 0% 4.5% ± 0.7% 0% 0% 0%
ch3F8-IgG4 0% 0% 6.1% ± 2.2% 0% 0% 0%
hu3F8-IgG4 0% 0% 3.1% ± 1.6% 0% 0% 0%
m3F8 0% 0% 4.1% ± 1.0% 0% 0% 0%
14.G2a 0% 0% 0% ± 0.9% 0% 0% 0%
Table6. Direct cytotoxicity of neuroblastoma cell line LAN-1 in the presence
of antibodies
Direct Cytotoxicity
Antibody EC50 (ug/ml)
ch3F8-IgG1 4.5 ± 1.2
hu3F8-IgG1 5.1 ± 1.2
ch3F8-IgG4 6.4 ± 1.8
hu3F8-IgG4 3.1 ± 0.0
m3F8 1.9 ± 0.2
14.G2a 47.1
Table7. Antibody potency relative to m3F8 in ADCC and CMC against
neuroblastoma LAN-1
Antibody PBMC PMN NK-92MI-CD16 NK-92MI-CD32 CMC
ch3F8-IgG1 390 18 24 13 0.64
hu3F8-IgG1 217 19 12 15 0.40
ch3F8-IgG4 0 1 0 3 0.01
hu3F8-IgG4 0 4 0 1 0.03
m3F8 1 1 1 1 1
14.G2a 0.03 1 4 2 0.12
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Table9. Targeting of
131I-labeled hu3F8 antibodies to LAN-1 xenografts in Biodistribution studies
LAN-1 % ID/gm Tumor to non-tumor ratio
m3F8 hu3F8-IgG1 hu3F8-IgG4 m3F8 hu3F8-IgG1 hu3F8-IgG4
N2 4 2 6 2 3 2 4 2 6 2 3
Organ Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM Mean SEM
Adrenal 2.5 0.3 3.1 0.5 2.5 0.5 12 2 11 1 11 2
Bladder 2.5 0.3 3.1 0.4 1.9 0.3 11 1 10 1 10 1
Blood 4.2 0.6 4.4 0.7 3.7 0.6 8 1 7 1 7 1
Brain 0.2 0.0 0.2 0.0 0.1 0.0 187 19 132 10 125 10
Femur 0.8 0.1 1.2 0.1 0.7 0.1 35 4 24 2 27 3
Heart 1.7 0.2 2.2 0.3 1.6 0.2 18 2 13 1 12 1
Kidney 1.8 0.2 2.3 0.3 1.6 0.2 16 2 13 1 10 1
Large Int 1.0 0.1 1.6 0.2 0.8 0.1 29 4 18 2 22 3
Liver 2.2 0.2 3.0 0.4 1.7 0.3 13 1 10 1 10 1
Lung 2.9 0.4 3.5 0.5 2.4 0.3 11 1 8 1 7 1
Muscle 0.6 0.1 0.9 0.1 0.5 0.1 44 4 33 3 33 3
Skin 2.1 0.3 4.0 0.6 1.9 0.3 14 2 8 1 9 1
Small Int 0.7 0.1 1.1 0.1 0.5 0.1 39 4 26 3 30 3
Spine 1.0 0.1 1.4 0.2 0.9 0.1 27 2 21 2 21 2
Spleen 4.2 0.6 3.9 0.5 1.3 0.1 9 1 8 1 12 1
Stomach 1.5 0.2 2.4 0.2 1.4 0.2 21 2 12 1 13 2
Tumor 28.6 4.2 29.6 3.8 16.0 1.9 1 0 1 0 1 0
Table8. Antibody potency relative to m3F8 in ADCC and CMC against seven neuroblastoma cell lines
LAN1 NMB7 SKNLP BE(1)N SKNMM SKNAS SKNJC2
Antigen density/cell 499348 932191 541522 1080289 98613 33512 16089
Antibody ADCC-NK92-CD16
ch3F8-IgG1 33.7 47.6 34.5 47.1 52.7 93.0 no killing
hu3F8-IgG1 13.9 31.3 11.8 35.7 28.6 30.7 no killing
ch3F8-IgG4 0.0 0.0 0.0 0.0 0.0 0.0 no killing
hu3F8-IgG4 0.0 0.0 0.0 0.0 0.0 0.0 no killing
m3F8 1.0 1.0 1.0 1.0 1.0 1.0 no killing
14G2a 2.1 1.0 1.0 1.3 0.1 0.0 no killing
ADCC-NK92-CD32
ch3F8-IgG1 14.6 4.8 393.9 25.9 82.3 13.4 no killing
hu3F8-IgG1 15.1 7.4 1469.3 61.6 58.3 13.1 no killing
ch3F8-IgG4 1.0 0.8 3.7 1.0 1.3 0.5 no killing
hu3F8-IgG4 0.8 0.5 19.8 1.1 1.0 0.0 no killing
m3F8 1.0 1.0 1.0 1.0 1.0 1.0 no killing
14G2a 2.2 2.3 66.9 4.0 1.0 0.3 no killing
CMC
ch3F8-IgG1 0.74 0.19 0.24 0.15 0.08 0.07 no killing
hu3F8-IgG1 0.40 0.27 0.59 0.20 0.22 0.11 no killing
ch3F8-IgG4 0.03 0.00 0.00 0.00 0.00 0.00 no killing
hu3F8-IgG4 0.01 0.00 0.00 0.00 0.00 0.00 no killing
m3F8 1.00 1.00 1.00 1.00 1.00 1.00 no killing
14G2a 0.46 0.05 0.10 0.01 0.01 0.02 no killing
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But more importantly, the preservation and enhancement of in
vitro effector function, as well as in vivo tumor targeting plus in
vivo therapeutic properties could be critical. Both ch3F8-IgG1
and hu3F8-IgG1 showed . 200 fold more efficient PBMC-
ADCC than m3F8, while PMN-ADCC was 19-fold. In sharp
contrast, for CMC, ch3F8 and hu3F8 had substantially lower
complement activating ability than m3F8.
This huge improvement in ADCC is most desirable, given
recent evidence for its role in the anti-tumor effects of MoAb
in patients. Among lymphoma patients treated with rituximab,
both high affinity FcR2A and FcR3A were shown to have better
response and survival advantage.
34 While the high affinity receptor
FcR3A translated into , 10 improvement in ADCC in vitro,
35
overall response and time to progression improved by 200%.
34
When metastatic breast cancer was treated with Herceptin,
patients with high affinity FcR3A had better overall response
(83% vs. 35%, p = 0.03), and longer progression-free survival
(p = 0.005).
36 For metastatic colorectal cancer treated with
cetuximab, patients with low affinity FcR2A and FcR3A had
comparable hazard ratios as patients with mutated KRAS.
37 Using
m3F8, patients with the high affinity FcR3A receptor on myeloid
cells were shown to have better survival.
38
While binding affinity and effector functions are critical for
therapeutic applications, cross-reactivity can pose unexpected
toxicity issues. We showed that these chimeric and humanized
forms for 3F8 had comparable cross-reactivity patterns as m3F8
both by ELISA assays with purified gangliosides, as well as by
immunohistochemistry on a panel of normal human tissues
(data not shown). Similar to m3F8, these engineered antibodies
showed low level of reactivity to GD1b when compared with
GD2. GD1b has been shown to be a highly prevalent ganglioside
among NB tumors, especially when differentiated by reti-
noids.
39,40 This may be relevant, since 13-cis-retinoic acid is
routinely given to patients undergoing immunotherapy for high
risk NB. However, anti-GD1b antibodies have also been asso-
ciated with sensory ataxic neuropathies.
41 Nevertheless, the safety
profile of m3F8 with no permanent or late sensory neuropathies
in more than 500 patients is reassuring.
CMC is unusually effective against human NB
42 because of its
low expression of CD55
8 and CD59.
9 All anti-GD2 antibodies
mediate efficient CMC, and m3F8 seems particularly effective.
Yet, several studies with rituximab have suggested a negative role
of complement activation in downregulating ADCC.
43 In clinical
studies, higher activity of complement component C1qA was
associated with less favorable response to rituximab therapy.
44
For anti-GD2 antibodies, complement activation was thought to
be responsible for the pain side effects;
45 hence the Fc-CH2
domain mutated version (hu14.18K322A) is currently in clinical
trial. Given these considerations, an overdrive of CMC is prob-
ably not desirable. It is reassuring that the increase in ADCC
efficiency of both ch3F8 and hu3F8 were not accompanied by
increased CMC.
In summary hu3F8 retains a slow koff, allowing them to remain
on tumor cell surface for longer periods. It mediates more potent
ADCC in vitro and anti-tumor activity in vivo, while maintaining
excellent targeting efficiency when compared with m3F8. By
leveraging ADCC over CMC, hu3F8 treatment could potentially
be made less painful, with reduced incidence or even avoidance
of neutralizing antibodies. Preliminary results of the Phase I
clinical trial of hu3F8 (Clinicaltrials.gov NCT01419834) have
confirmed the low immunogenicity of hu3F8, with highly
favorable pharmacokinetics.
Figure2. Treatment of LAN-1 subcutaneous neuroblastoma xenografts in athymic nude mice. Antibodies were administered intravenously twice weekly
for a total of 8 doses. m3F8 and control mouse IgG3 had no effect on tumor growth. 100–200 ug of hu3F8-IgG1 had the strongest anti-tumor effect
(p , 0.05, student t-test after day 21 of treatment), whereas such effect was substantially less if 20 ug was used.
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Materials and Methods
Cell culture and human tissues. Human NB cell line LAN-1
was provided by Dr Robert Seeger (Children’s Hospital of Los
Angeles), and NB1691 by Dr Peter Houghton (St. Jude
Children’s Research Hospital). NK-92MI was obtained from
American Type Culture Collection (ATCC). All cell lines were
grown in F10 [RPMI 1640 medium supplemented with 10%
fetal bovine serum (Hyclone, South Logan, UT), 2 mM
glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin
at 37°C in a 5% CO2 incubator. Normal tissues as well as
solid tumor samples of different histological types obtained
at Memorial Sloan-Kettering Cancer Center (MSKCC) were
snap-frozen in liquid nitrogen.
Monoclonal antibodies. m3F8 was a mouse IgG3 antibody
with kappa light chain,
15 its anti-NB activity has been previously
described.
15,46,47 It was produced as ascites and purified by affinity
chromatography: protein A (GE Healthcare) with . 90% pure
by SDS-PAGE. Anti-GD2 hybridoma ME36.1 was obtained
from ATCC. 14.G2a was purchased from BD Biosciences.
Construction of the hu3F8-IgG1, hu3F8-IgG4, ch3F8-IgG1,
and ch3F8-IgG4 antibody producer lines. Based on human
homologs of m3F8, CDR sequences of both heavy and light
chains of m3F8 were grafted into the human IgG1 framework
and optimized. These hu3F8 genes were synthesized for CHO
cells (Blue Heron Biotechnology or Genscript). Using the blue-
script vector (Eureka, CA), these heavy and light chain genes of
hu3F8 were transfected into DG44 cells and selected with G418
(InVitrogen, CA). Similarly, mouse VH and VL sequences were
grafted onto human IgG1 and IgG4 frameworks to make the
ch3F8-IgG1 and ch3F8-IgG4 recombinant antibodies. From two
heavy chain and two light chain designs, four versions of hu3F8
genes were synthesized and expressed in DG44 cells. Based on
in vitro stability, binding kinetics to GD2 by Biacore, and
efficiency in ADCC, the final heavy and light chain sequences
of hu3F8-IgG1 were chosen.
Purification of Hu3F8 and ch3F8. Hu3F8 and ch3F8
producer lines were cultured in Opticho serum free medium
(InVitrogen) and the mature supernatant harvested. Protein A
affinity column was pre-equilibrated with 25 mM sodium
citrate buffer with 0.15 M NaCl, pH 8.2. Bound hu3F8 was
eluted with 0.1 M citric acid/sodium citrate buffer, pH 3.9 and
alkalinized (1:10 v/v ratio) in 25 mM sodium citrate, pH 8.5. It
was passed through a Sartobind-Q membrane and concentrated
to 5–10 mg/ml in 25 mM sodium citrate, 0.15 M NaCl, pH 8.2.
Stability studies were performed on hu3F8-IgG1 in 25 mM
sodium citrate 0.15 M NaCl pH 8.2 vs. PBS pH 7.4 in the
presence or absence of 0.7 mg/ml of Tween 80 (Sigma). Two
micrograms each of the proteins was analyzed by SDS-PAGE
under non-reducing or reducing conditions using 4–15% Tris-
Glycine Ready Gel System (Bio-Rad). Invitrogen SeeBlue Plus2
Pre-Stained Standard was used as the protein molecular weight
marker. After electrophoresis, the gel was stained using PIERCE’s
GelCode Blue Stain Reagent. The gel was scanned using Bio-
Rad Fluor-S MultiImager (Bio-Rad), and the band intensity
quantified with Quantity One software (Bio-Rad).
Quantitation of hu3F8 and ch3F8 by ELISA. Microtiter
plates were coated with GD2 at 20 ng per well. 150 ml per well
of 0.5% BSA in PBS (diluent) was added to each plate for at
least 30 min at ambient temperature to block excess binding
sites. A purified batch of hu3F8-IgG1 was used to construct a
standard curve starting at 0.5 mg/ml followed by 2-fold dilutions.
100 ml of standard and samples (also diluted 2-fold) were added
to each well and incubated for 2.5 h at 37°C. After washing the
plates with PBS, 100 ml of goat anti human-IgG (H
+L) (Jackson
Research Laboratory) diluted at 1:3500 in diluent was added to
each well and incubated for 1 h at 4°C. ELISA color reaction
was developed with chromogen OPD (Sigma) with the substrate
hydrogen peroxide for 30 min at room temperature (RT) in the
dark. The reaction was stopped with 5N H2S04 and the optical
density (OD) read with ELISA plate reader MRX (Dynex) at
490 nm. Based on the standard curve, quantitation of hu3F8
and ch3F8 supernatants was calculated in micrograms/milliliters
or micrograms/milligrams of protein.
In vitro binding kinetics by Biacore T-100 Biosensor (Biacore
AB of GE Healthcare). CM5 sensor chip (Research grade) and
related reagents were purchased from Biacore USA. The ganglio-
sides GM1 was from ALEXIS Biochemicals (AXXORA L.L.C.),
and GD2 from Advanced ImmunoChemical. In brief, ganglio-
sides were directly immobilized onto the CM5 sensor chip via
hydrophobic interaction.
48,49 Reference surface was immobilized
with GM1. Active surface was immobilized with GD2 and GM1
in 1:1 ratio. Diluted mixture of GD2 and GM1 (50 mg/ml) was
injected (300 ml) at a flow rate of 15 ml/min over 20 min.
Extensive washing was followed with 10 mM NaOH (typically
five washes of 20 ml at a flow rate of 5 ml /min) until a stable
baseline was obtained.
Purified anti-GD2 MoAb were diluted in HBS-E buffer con-
taining 250 mM NaCl at varying concentrations (50 ~1600 nM)
prior to analysis. Samples (60 ml) were injected over the sensor
surface at a flow rate of 30 ml/min over 2 min. Following
completion of the association phase, dissociation was monitored
in HBS-E buffer containing 250 mM NaCl for 300 sec at the
same flow rate. At the end of each cycle, the surface was regener-
ated using 50 ml 20 mM NaOH at a flow rate of 50 ml/min over
1 min and 100 ml 4M MgCl2 at a flow rate of 50 ml/min over
2 min. The biosensor curves obtained following injection of
the samples over immobilized GD2 were subtracted with the
control curves obtained with the samples injected over immobi-
lized GM1 prior to kinetics analysis. The data were analyzed by
the bivalent analyte model and default parameter setting for the
rate constants using the Biacore T-100 evaluation software, and
the apparent association on rate constant (kon), dissociation off
rate constant (koff) and equilibrium dissociation constant (KD =
koff/kon) were calculated.
ELISA for cross-reactivity with other gangliosides. GD2,
GM2, GD1a, GD1b, GT1b, GD3, as well as GQ1b were coated
on polyvinyl microtiter plates at 20 ng per well in 90% ethanol.
Following air drying, wells were blocked with 0.5% BSA in PBS
at 150 ml per well for 1 h at room temperature. Antibodies were
added in triplicates at 1 mg/ml (100 ml per well) in 0.5% BSA.
For background subtraction, wells with (1) no antigen and (2) no
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sample were used. Following incubation for 2 h at 37°C and
washing with PBS, HRP-goat anti-mouse IgG at 1:1000 dilution
for mouse antibodies or HRP-goat anti-human IgG at 1:1000
dilution for humanized antibodies, all from Jackson Research
Laboratory, were added. After incubation for 1 h at 4°C and
further washing, color reaction was performed and OD was
read using ELISA plate reader at 490 nm, and cross-reactivity
expressed as % maximal binding to GD2.
Direct cytotoxicity. Antibodies were tested for their direct
effect on tumor cell growth and survival in the absence of
human serum or human effector cells. Tumor targets were
dissociated with 2mM EDTA or Trypsin-EDTA, washed and
plated onto 96-well flat bottom plates in F10 at 1.2  10
3 to
3.5  10
4 per well. After incubation for 24 h in a 5% CO2
incubator at 37°C, increasing concentrations of antibodies in
F10 are added to each well. Control wells received F10 alone.
After incubation for 72 h at 37°C in 5% CO2, WST-8 reagent
(Cayman Chemical Co.). was added to each well and incubated
in the dark in a CO2 incubator at 37°C for 2–6 h. OD was read
at 450 nm and 690 nm using ELISA plate reader. WST-8 assay
was validated using direct cell counting using Trypan Blue
(Sigma) or Beckman Coulter Counter (Beckman Coulter).
Antibody-dependent cell-mediated cytotoxicity (ADCC) by
51Chromium Release. Target cells were detached with 2 mM
EDTA in Ca2
+ Mg2
+ free PBS and washed in F10. Antigen
density was estimated using Quantum Simply Cellular anti-
Mouse IgG beads according the manufacturer’s instructions
(Bangs Laboratories, Inc.). For cytotoxicity assays, 100 mCi of
51Cr was incubated with 10
6 target cells in a final volume of
250 ml and incubated for 1 h at 37°C with gentle resuspension
of pellet at 15 min intervals. Cells were then washed and
resuspended in 250 ml F10 and incubated for 30 min at 37°C.
After washing, cells were counted and viability determined with
Trypan Blue and quickly plated onto 96 well U-bottom plates.
Peripheral blood from normal volunteers was collected into
heparinized tubes. Blood was mixed with 3% dextran/PBS and
kept at room temperature for 20 min to sediment the red cells.
White cells were then ficolled and separated into peripheral
blood mononuclear cells (PBMC) and polymorphonuclear
leukocytes (PMN) for PBMC-ADCC and PMN-ADCC, respect-
ively. Cells were washed in F10, counted and viability deter-
mined. PBMC-ADCC was done in the presence of 10 U/ml of
IL-2 and PMN-ADCC in 2 ng/ml of GM-CSF. Antibodies were
diluted in F10 from 1 mg/ml in 10-fold dilutions. Plates were
incubated in a 37°C, 5% CO2 incubator for 4 h. Released
51Cr
in the ADCC supernatant was collected for gamma counting.
Total release was determined using 10% sodium dodecyl sulfate
(SDS) and background spontaneous release was determined
with F10 only without effectors. An effector:target (E:T) ratio
of 50:1 was generally used. Similarly, ADCC assays were
performed using NK-92MI cells stably transfected with the
human CD16 or human CD32 Fc receptors. Unlike PBMC or
PMN, no cytokines were needed in the assay. E:T ratio was
generally kept at 20:1.
Biodistribution of MoAb in xenografted mice. Female
athymic nude mice were purchased from Harlan Spraque
Dawley, Inc. All procedures were performed in accordance with
the protocols approved by our Institutional Animal Care and
Use Committee and institutional guidelines for the proper and
humane use of animals in research. LAN-1 tumor cells were
harvested and resuspended in Matrigel (BD Biosciences). Cells
(2 ~10  10
6) were implanted subcutaneously (sc) to the flank of
the mice in 0.1 ml volume using 22-gauge needles. Tumors were
allowed to grow to the size of ~200 mm
3 before initiating
treatment. Mice with established tumors were randomly separated
into treatment groups. 100 mCi of radioiodinated antibody per
mouse was injected intravenously and animals sacrificed usually
at 48 h, and their organs removed and counted in a gamma
counter (Packard Instruments, Perkin Elmer). These organs
included skin, liver, spleen, kidney, adrenal, stomach, small
intestine, large intestine, bladder, femur, muscle, tumor, heart,
lung, spine, and brain. Based on the mCi accumulated in the
organ and the organ weight, % injected dose (ID)/gm of mouse
was calculated. Tumor to non-tumor ratios of % ID/gm was also
calculated.
Therapy of LAN-1 neuroblastoma xenografts. Studies com-
menced when sc tumors reached ~200 mg. Mice were randomly
assigned to treatment groups (n = 5). Antibodies were administered
intravenously (iv) twice a week for a total of eight doses. Tumor
volume and bodyweightweremeasuredtwice per week. Differences
between tumor sizes were tested for significance by Student’s t-test.
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